Infinitopes

Infinitopes Precision Immunomics is a clinical-stage cancer biotechnology company spun out from the University of Oxford and supported by Cancer Research UK (CRUK). The company was founded in 2021 to address one of oncology's most significant unmet needs: preventing the cancer metastases that cause 70–90% of all cancer deaths. Despite decades of research, no accessible, off-the-shelf cancer vaccine has succeeded in durable prevention of recurrence at scale — the problem Infinitopes was built to solve.

Infinitopes' Precision Immunomics™ platform combines two world-leading capabilities: an AI/ML-driven immunopeptidomics approach to discover highly specific tumour antigen targets, and a high-efficiency viral vector delivery system that generates durable CD8+ T-cell immunity. Unlike personalised cancer vaccines — which are expensive and slow to manufacture — Infinitopes' vaccines are designed to be off-the-shelf, accessible, and scalable across multiple cancer types.

The company's lead candidate, ITOP1, is a precision cancer vaccine targeting oesophageal adenocarcinoma, one of the UK's deadliest cancers. In April 2025, Infinitopes received MHRA approval to begin a Phase I/IIa clinical trial across four NHS university cancer centres — the first of its kind from Oxford. Since incorporation, Infinitopes has raised over $35 million from investors including Octopus Ventures, Amplify Bio, Cancer Research Horizons, Kindred Capital, Macmillan Cancer Support, Saras Capital, and Wilbe Capital.